Latest news with #PaulMatteis
Business Insider
3 days ago
- Business
- Business Insider
Analysts Are Bullish on Top Healthcare Stocks: Neurogene (NGNE), Cogent Biosciences (COGT)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurogene (NGNE – Research Report) and Cogent Biosciences (COGT – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Neurogene (NGNE) Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurogene on July 7 and set a price target of $46.00. The company's shares closed last Friday at $21.43, close to its 52-week low of $13.47. According to Matteis is a 3-star analyst with an average return of 2.8% and a 43.2% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Sionna Therapeutics, Inc., KalVista Pharmaceuticals, and BioMarin Pharmaceutical. Currently, the analyst consensus on Neurogene is a Strong Buy with an average price target of $38.20, implying a 76.5% upside from current levels. In a report issued on June 30, BMO Capital also maintained a Buy rating on the stock with a $26.00 price target. Cogent Biosciences (COGT) In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Cogent Biosciences, with a price target of $20.00. The company's shares closed last Friday at $10.98. According to Slutsky has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -2.6% and a 38.8% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Abivax SA Sponsored ADR, and Olema Pharmaceuticals. Cogent Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $18.64, a 74.7% upside from current levels. In a report issued on June 30, Citi also maintained a Buy rating on the stock with a $15.00 price target.
Business Insider
22-06-2025
- Business
- Business Insider
Stifel Nicolaus Sticks to Their Buy Rating for Alkermes (ALKS)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alkermes (ALKS – Research Report), with a price target of $42.00. The company's shares closed last Friday at $29.09. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Matteis is a 3-star analyst with an average return of 1.2% and a 41.20% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Alkermes, Neurocrine, and uniQure. In addition to Stifel Nicolaus, Alkermes also received a Buy from UBS's Ashwani Verma in a report issued on June 17. However, on June 10, RBC Capital maintained a Hold rating on Alkermes (NASDAQ: ALKS).
Reuters
07-04-2025
- Health
- Reuters
Rhythm Pharma's drug for rare obesity meets late-stage trial goal
April 7 (Reuters) - Rhythm Pharmaceuticals (RYTM.O), opens new tab said on Monday its drug Imcivree notably reduced weight in patients with a rare obesity disorder caused by damage to the brain, meeting the main goal of a late-stage trial. Shares of the company rose 2.5% to $48.10 in premarket trading despite U.S. index futures being sharply lower. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. The 120-person trial tested patients with acquired hypothalamic obesity, a condition caused by damage to the hypothalamus in the brain, often due to tumors, their treatment or other injuries. The therapy, chemically known as setmelanotide, reduced weight by 16.5% as measured on the body mass index (BMI) after a year, compared to a 3.3% increase for patients on placebo, the company said in a statement. Imcivree is Rhythm's only approved treatment, and an expanded approval for the rare disorder could unlock a $2 billion-plus opportunity, according to Jefferies analysts. The drug brought in sales of $41.8 million in the fourth quarter of 2024. Imcivree is currently approved to treat genetic obesity in adults and children aged two years and older. The weight loss seen in the trial is "very strong, looks highly consistent and clears investor expectations, setting up a blockbuster expansion opportunity," said Stifel analyst Paul Matteis. The efficacy of the drug is "outstanding in a highly difficult-to-treat patient population," Matteis added. Rhythm estimates there are 5,000 to 10,000 people living with hypothalamic obesity in the U.S. The therapy also met secondary goals such as improvements in daily maximal hunger score, a measure of the intensity of hunger, for patients aged 12 years or older. The company expects to complete regulatory applications in the United States and Europe in the third quarter of this year.
